•  
  •  
 

Article Type

Original Study

Abstract

Objective This work aimed to study CD305 and CD38 expression in chronic lymphocytic leukemia (CLL) patients and its relation to clinical and prognostic criteria of the disease. Background CD305 is an inhibitor of B-cell receptor mediated signaling, and has been reported to be of lower expression in high risk CLL patients. Studies addressing CD305 in CLL and its relation to biological variables and standard prognostic factors had been so scarce yet .On the other hand, CD38 expression, a well established prognostic factor, in CLL, is associated with an aggressive clinical behavior. Patient and methods Our study included 54 patients. Forty CLL consecutive patients and 14 age-matched and sex-matched apparently healthy controls. Clinical examination and laboratory investigations were done for all of the studied groups. Results CD305 showed a positive correlation with lymphocyte doubling time. However it showed a negative correlation with; β2microglobulin, lactate dehydrogenase, modified ray staging and Coombs' test. CD38 expression showed a positive significant correlation with modified ray staging, white blood cells, β2microglobulin, lactate dehydrogenase and Coomb's test however it showed a negative correlation with CD305 and lymphocyte doubling time. 55% of patients did not receive chemotherapy were CD305 positive. The remaining 45% of patients received chemotherapy and were CD38+. Conclusion CD305 and CD38 expression can be used as simple reliable, inexpensive independent prognostic factors in CLL patients and they can even predict at presentation patients who will initiate chemotherapy early.

Download

Share

COinS